7,756 Shares in Elevance Health, Inc. $ELV Bought by North Dakota State Investment Board

North Dakota State Investment Board bought a new position in Elevance Health, Inc. (NYSE:ELV) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 7,756 shares of the company’s stock, valued at approximately $2,719,000.

Other institutional investors have also recently bought and sold shares of the company. Murphy Middleton Hinkle & Parker Inc. bought a new position in Elevance Health in the 4th quarter worth $5,941,000. Evergreen Wealth Management LLC raised its holdings in Elevance Health by 33.5% in the 3rd quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock worth $5,584,000 after acquiring an additional 4,336 shares during the period. Blume Capital Management Inc. raised its holdings in Elevance Health by 236.7% in the 3rd quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock worth $1,986,000 after acquiring an additional 4,320 shares during the period. Victory Capital Management Inc. grew its position in Elevance Health by 31.1% in the 3rd quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock worth $149,182,000 after purchasing an additional 109,462 shares during the last quarter. Finally, Caprock Group LLC acquired a new stake in Elevance Health in the 3rd quarter worth $1,638,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of Elevance Health stock opened at $393.35 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The firm’s 50-day simple moving average is $325.02 and its 200-day simple moving average is $334.34. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $412.96. The firm has a market cap of $85.42 billion, a P/E ratio of 16.73, a price-to-earnings-growth ratio of 2.23 and a beta of 0.66.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. During the same period in the previous year, the business earned $11.97 EPS. The firm’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, research analysts expect that Elevance Health, Inc. will post 26.79 EPS for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is 29.26%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ELV shares. UBS Group set a $400.00 price target on shares of Elevance Health in a research report on Thursday, January 29th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Elevance Health from $332.00 to $363.00 and gave the stock a “hold” rating in a research report on Thursday, April 23rd. Leerink Partners set a $364.00 price target on shares of Elevance Health in a research report on Thursday, April 23rd. Robert W. Baird raised their price target on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research report on Thursday, April 23rd. Finally, Royal Bank Of Canada lowered shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target on the stock. in a research report on Tuesday, February 3rd. Thirteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $384.58.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.